GUIDED THERAPEUTICS, INC.
Table of Contents

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): February 13, 2009 (February 10, 2009)

GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction of Incorporation)		 0-22179
(Commission File Number) 		58-2029543
(IRS Employer Identification No.)
 

4955 Avalon Ridge Pkwy, Suite 300
Norcross, Georgia
(Address of Principal Executive Offices)

 30071
(Zip Code)

Registrant's Telephone Number, Including Area Code:     (770) 242-8723

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                                    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o                                    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o                                    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o                                    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 

TABLE OF CONTENTS

Item 8.01. Other Events.
 

Item 9.01. Financial Statements and Exhibits.
Exhibit Index
Exhibit 99.1
SIGNATURES

Table of Contents

Item 8.01.          Other Events.

On February 10, 2009, Guided Therapeutics, Inc. ("GT") reported that that its LightTouch™ non-invasive cervical cancer detection technology properly identified cervical disease missed by Pap tests and conventional pathology in a multi-site Food and Drug Administration (FDA) pivotal clinical trial.  Based on the outcome of the study, GT plans to submit the trial results to the FDA as part of the Premarket Approval (PMA) application for the LightTouch, as more fully described in the press release, a copy of which is furnished as Exhibit 99.1 hereto and which information is incorporated herein by reference.

Table of Contents

Item 9.01.       Financial Statements and Exhibits.

           (d)        Exhibits.
            The following exhibits are filed with this report:

 

Exhibit No.

Exhibit Description

99.1

Press Release, dated February 10, 2009

 

Table of Contents

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    GUIDED THERAPEUTICS, INC.
 
   
/s/ MARK L. FAUPEL
    By:   Mark L. Faupel, Ph.D.
        CEO & President
 
Date: February 13, 2009